Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. XOMA
XOMA logo

XOMA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Xoma Royalty Corp (XOMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
31.370
1 Day change
3.70%
52 Week Range
39.920
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Xoma Royalty Corp (XOMA) is not a strong buy for a beginner, long-term investor at this moment. Despite a positive analyst rating and a significant YoY revenue increase, the stock's overbought RSI, declining net income, and lack of strong trading signals or positive catalysts suggest waiting for a better entry point.

Technical Analysis

The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is at 80.257, signaling the stock is overbought. The stock is trading near its first resistance level (R1: 30.766), with converging moving averages suggesting indecision in the trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
10

Positive Catalysts

  • Analyst Leerink raised the price target to $50 from $45 and maintained an Outperform rating. Revenue increased by 57.87% YoY in Q4 2025.

Neutral/Negative Catalysts

  • Net income dropped significantly by -162.29% YoY, and EPS fell by -157.78% YoY. The stock is overbought based on RSI, and there are no recent news or significant trading trends from insiders or hedge funds.

Financial Performance

In Q4 2025, revenue increased to $13.76M, up 57.87% YoY. However, net income dropped to $3.32M (-162.29% YoY), and EPS fell to 0.26 (-157.78% YoY). Gross margin remained steady at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Leerink raised the price target to $50 from $45 and maintained an Outperform rating, showing confidence in the stock's long-term potential.

Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
Wall Street analysts forecast XOMA stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.250
sliders
Low
50
Averages
71
High
97
Current: 30.250
sliders
Low
50
Averages
71
High
97
Leerink
Outperform
upgrade
$45 -> $50
AI Analysis
2026-02-24
Reason
Leerink
Price Target
$45 -> $50
AI Analysis
2026-02-24
upgrade
Outperform
Reason
Leerink raised the firm's price target on Xoma to $50 from $45 and keeps an Outperform rating on the shares.
Lucid Capital
NULL -> Buy
initiated
$76
2025-12-09
Reason
Lucid Capital
Price Target
$76
2025-12-09
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Xoma with a Buy rating and $76 price target. The company has assembled a royalty portfolio from six commercial and nine Phase 3- stage small molecule and biological assets, the analyst tells investors in a research note. The firm says Xoma expects to collect over $1B in milestones and royalties over the next 15 years. Lucid believes that by building a diversified portfolio, the company mitigates single-asset risk while retaining exposure to substantial long-term value creation.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XOMA
Unlock Now

People Also Watch